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MODIFIKASI HEMODINAMIK RENAL TIKUS KEGAGALAN GINJAL 
CYCLOSPORINE A TERARUH OLEH  
TEMPOL 
 
ABSTRAK 
Peningkatan bukti menunjukkan bahawa tekanan oksidatif yang terlibat 
dalam patogenesis pelbagai penyakit kardiovaskular termasuk tekanan darah tinggi 
dan kegagalan ginjal. Tekanan oksidatif mungkin menyumbang kepada 
perkembangan penyakit ginjal secara tidak langsung dengan meningkatkan kadar 
atau secara langsung meransang kerosakan glomerular dan iskemia. Kegagalan 
kardiovaskular yang disebabkan oleh tekanan oksidatif dalam penyakit buah 
pinggang telah meningkatkan secara mendadak dan konsep ini semakin mendapat 
banyak perhatian. Tempol-superoxide dismutase (SOD) mimetic, berkesan dalam 
memerangkap radikal bebas. SOD memangkin penukaran O2- kepada H2O2, yang 
kemudian ditukarkan kepada air melalui tindak balas katalase. Kajian ini telah 
dijalankan untuk mengkaji kesan potensi Tempol ke atas fungsi dan hemodinamik 
teraruh oleh CsA kegagalan ginjal dan CsA model hipertensi teraruh L-NAME. 64 
tikus jantan Sprague-Dawley telah dibahagikan secara rawak kepada lapan 
kumpulan. Model kegagalan ginjal telah dihasilkan dalam kumpulan yang terpilih 
menggunakan CsA pada dos 25 mg / kg / hari secara oral. Manakala model hipertensi 
kekurangan nitrik oksida (NOx) telah dicipta menggunakan L-NAME pada dos 15 
mg / kg / hari secara oral dalam kumpulan yang terpilih. Tekanan darah di bawah 
sedar telah diukur menggunakan kaedah tail cuff plethysmography secara mingguan 
sepanjang tempoh kajian. Selain itu, data metabolik, parameter fungsi ginjal turut 
dikaji. Di samping itu, nadi halaju gelombang dan tindak balas vasokontriksi renal 
kortikal keatas noradrenalin, phenylephrine, methoxamine dan angiotensin II telah 
diperhatikan semasa kajian akut. Tambahan pula, plasma malondialdehyde, 
xxii 
 
superoxide dismutase, nitric oxide dan total antioxidant capacity telah digunakan 
untuk menentukan tekanan oksidatif. Data analisis, mean ± SEM menggunakan 
one/two-way ANOVA dengan signifikasi pada tahap p<0.05. Rawatan CsA, rawatan 
L-NAME pada tikus normal dan tikus kegagalan ginjal tikus telah menunjukkan 
hipertensi yang signifikan, kemerosotan fungsi ginjal dan tekanan oksidatif 
dibanding dengan tikus kawalan. Tambahan lagi, rawatan CsA, rawatan L-NAME 
pada tikus normal dan tikus kegagalan ginjal menunjukkan penurunan tindakbalas 
vasokontriksi ginjal keatas noradrenalin, phenylephrine, methoxamine dan 
angiotensin II dibandingkan dengan tikus SD kawalan normal. Rawatan Tempol 
menjadikan tekanan darah normal, memperbaiki kegagalan gingal dan meningkatkan 
pertahanan antioksidan dalam tikus rawatan CsA dan L-NAME dibanding dengan 
tikus yang tidak menerima rawatan. Selain itu, rawatan Tempol juga meningkatkan 
tindak balas vasokontriksi ginjal keatas noradrenalin, phenylephrine, methoxamine 
dan angiotensin II dibandingkan dengan kumpulan yang tidak dirawat. Penemuan ini 
menunjukkan bahawa rawatan kronik CsA dan L-NAME mengurangkan kepekaan 
vaskular pada α1-adrenergic agonis dan angiotensin II. Di samping itu, sub-unit α1A-
adrenoceptor dianggap tidak terlibat dalam pengantaraan kegagalan ginjal CsA. α1-
adrenoceptors dan angiotensin II memainkan peranan penting dalam kawalan 
hemodinamik ginjal pada tikus kegagalan ginjal CsA dan hipertensi teraruh L-
NAME. Kesimpulannya, SOD adalah predominant superoxide scavenger jika 
dibandingkan dengan NOx.  
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MODIFICATION OF RENAL HAEMODYNAMICS IN CYCLOSPORINE A - 
INDUCED RENAL FAILURE RATS BY TEMPOL 
 
ABSTRACT 
 Increasing evidence suggests that oxidative stress is involved in the 
pathogenesis of a wide range of cardiovascular diseases including hypertension and 
renal failure. Oxidative stress may contribute to the progression of renal diseases 
indirectly by aggravating hypertension or directly by inducing the glomerular 
damage and ischemia. The deleterious cardiovascular effects due to oxidative stress 
in chronic renal failure are dramatically increasing and this concept is gaining much 
attention. Tempol is a redox-cycling nitroxide namely superoxide dismutase (SOD) 
mimetic that promotes the metabolism of many reactive oxygen species (ROS) and 
improves nitric oxide bioavailability.  SOD catalyzes the conversion of O2- to H2O2, 
which converts into water by catalase reaction. The present study was undertaken to 
investigate the potential effect of Tempol on the renal functional and haemodynamics 
in Cyclosporine A-induced renal failure and L-NAME induced hypertension models. 
64 male Sprague-Dawley rats were randomly divided into eight groups (n=8). Renal 
failure model was produced in selected groups using CsA at a dose of 25 mg/kg/day 
p.o. Nitric oxide (NOx) deficiency hypertensive model was created using L-NAME 
at a dose of 15 mg/kg/day p.o in selected groups. Conscious blood pressure was 
measured using tail cuff plethysmography method weekly throughout the study 
period.  Besides that, metabolic data, renal functional parameters were studied. 
Moreover, pulse wave velocity and renal cortical vasoconstriction responses to 
noradrenaline, phenylephrine, methoxamine and angiotensin II were observed during 
acute study. In addition, plasma malondialdehyde, superoxide dismutase, nitric oxide 
and total antioxidant capacity levels were used to determine the oxidative stress. 
xxiv 
 
Data, mean±SEM were subjected to one/two-way ANOVA with significance level at 
P<0.05. CsA treated, L-NAME treated normal and renal failure rats developed 
significant hypertension, deteriorated renal functional parameters and oxidative stress 
as compared to control.  Furthermore, CsA treated, L-NAME treated normal and 
renal failure rats exhibited reduction in renal vasoconstrictor response to 
noradrenaline, phenylephrine, methoxamine and angiotensin II compared to normal 
SD control rats. Tempol treatment normalized the blood pressure, ameliorates the 
renal insufficiency and up-regulates the antioxidant defenses in both CsA and L-
NAME treated rats as compared to non-treated counterparts. Moreover, Tempol 
treatment also increased the renal vasoconstrictor response to noradrenaline, 
phenylephrine, methoxamine and angiotensin II as compared to those renal failure 
control rats. These findings suggest that chronic administration of CsA and L-NAME 
blunts the vascular sensitivity to α1-adrenergic agonists and angiotensin II. In 
addition to that, α1A-adrenoceptor is not the functional subtype that mediates renal 
vasoconstriction response in CsA-induced renal failure rats. α1-adrenoceptors and 
angiotensin II play a pivotal role in regulation renal haemodynamics in CsA-induced 
renal failure and L-NAME induced hypertension. This study concluded that SOD 
was the predominant superoxide scavenger as compared to NOx. 
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CHAPTER 1 
INTRODUCTION 
1.1 Kidney 
1.1.1 The gross anatomy  
The human kidneys are paired bean shaped and each kidney is measures about 
11.25 cm in length, 5 to 7.5 cm in breadth and more than 2.5 cm in thickness by which it 
is approximately as big as the fist of an adult human. The exact position of a human 
kidney is at the posterior part of the abdomen, one on either side of the vertebral column, 
behind the peritoneum at about the level of the 12th rib just above the waistline, thus it is 
retroperitoneal (Standring et al., 2005). Each kidney weighs is about 115-170 grams 
where its combined weight is less than 1% of the total body weight of an adult human. 
 
The cross section of the kidney shows two major regions with the outer layer 
called the renal cortex which is reddish brown in colour. Whereas, the dark brown inner 
layer is called the renal medulla and is striped on the its surface (Shier, 2003). The renal 
medulla is then further subdivided into a number of conical sections called renal 
pyramid with the papillae tubules called collecting ducts which drain into a single 
funnel-shaped passage to the initial portion of the ureter called the renal pelvis (Drake et 
al., 2005).  
 
Deep down to the renal pyramids, there are millions of microscopic subunits 
called nephrons, which are the functional units for blood filtration and urine formation. 
Each particular nephron is composed of a renal corpuscle and renal tubule which filter 
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the blood and form urine respectively. Eventually the filtrate is modified and excreted in 
the form of urine. The renal corpuscle consists of the inflow subunit called Bowman’s 
capsule and a turf of capillaries called glomerulus which is the original site for blood 
filtration and tubular fluid formation (Hall & Guyton, 2006a). Blood enters the 
glomerular capillaries through the afferent arteriole and exit via the efferent arteriole to 
produce protein free plasma filtrates via a process of glomerular filtration. This filtrate 
then flows into the first part of the tubular region of the nephron, the proximal 
convoluted tubule and further empties into the hairpin loop tubules located in the 
medulla region known as descending and ascending limbs of loop of Henle. From the 
ascending loop of Henle, the filtrate then enters the distal convoluted tubules which 
actually resembles the proximal one but this tubule is shorter. Later, the fluid enters a 
short straight terminal segment of the nephron called the connecting tubule that joins the 
nephron to the collecting duct. The collecting ducts then empty the filtrates into the 
calyces and the filtrate is excreted in the form of highly concentrated urine via the 
urinary system (Martini, 2001).  
 
Despite the size of the kidney which is relatively small, the blood supply to this 
organ is approximately 22% of the cardiac output. The blood flows into the renal artery 
and branches into other segmental arteries which in turn flows into another type of artery 
called interlobar arteries. From here, the blood is further fed into the arcuate arteries and 
branch into the last segment called interlobular arteries where the blood is supplied to 
individual nephron. The renal glomerular ultrafiltration process in the renal corpuscle is 
driven by the Starling forces existing across the walls of glomerular capillaries. After the 
filtration process, the blood is transported into small capillary beds namely peritubular 
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capillaries which branch from the efferent arterioles that are located close to the renal 
tubules and vasa recta which run along the loops of Henle and collecting duct deep into 
the renal medulla. As in the arteriole distribution, the filtered blood is then drained into 
the interlobular veins from the peritubular capillaries and vasa recta. At this point, blood 
is transported away from the nephrons by arcuate veins to the interlobar veins and renal 
vein eventually returns to inferior vena cava (Meyer et al., 2004).  
 
 
1.1.2 The physiology of kidney 
The principal function of the kidney is to preserve the constancy of the body’s 
interior environment by excreting waste products and regulating the electrolyte contents, 
volume and pH of the extracellular fluid due to the consequence of the varying internal 
and external environments as well as dietary intake (Dantzler, 1989). 
 
The normal kidney receives almost a quarter of the cardiac output from more 
than hundred liters of plasma daily and performs its task by simple mechanisms, i.e. 
filtration, reabsorption, and secretion that happen in the nephron. Water and solutes are 
exchanged between fluid and plasma in the renal tubules to regulate the composition of 
plasma. Filtration occurs in the renal corpuscle which is the mass flow of protein free 
plasma from the glomerular capillaries into the Bowman’s capsule. Reabsorption is done 
by the selective transport of glomerular filtrate from the lumen of the tubules to the 
interstitial cells outside the tubules. Whereas, secretion is the reverse mechanism by 
which molecules from the peritubular fluid is transported back into the lumen of the 
renal tubules (Guyton & Hall, 1991). 
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Glomerular filtration rate describes the flow rate of filtered fluid through the 
kidney. Specifically, it estimates how much blood passes through the tiny filters in the 
kidneys, called glomeruli, each minute. Under the normal condition, the regulation of 
the glomerular filtration rate involves three intrinsic control mechanisms which includes 
myogenic regulation of smooth muscle in the afferent arteriole, tubuloglomerular 
feedback and mesangial cell contraction. In contrast, extrinsic control includes the 
sympathetic nervous control of smooth muscle in the afferent and efferent arterioles 
(Rang et al., 2007).  
 
The kidney works in integration with other systems in the body, i.e. 
cardiovascular and respiratory systems. The renal and respiratory system regulates acid-
base balance which is very important for normal protein function. Likewise, the 
interaction of renal and cardiovascular system is crucial for the maintenance of blood 
pressure. Moreover, the kidney interacts with the endocrine system to secrete renin 
which is required for the activation of angiotensin II. Through these interactions, the 
kidney is involved in long term regulation of blood pressure, water and electrolyte 
balance (Germann et al., 2005b).  
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  Figure 1.1: Anatomy and blood supply of kidney. 
(A)  A cross section of a kidney showing the renal cortex and renal medulla with the 
magnified view of renal pyramid. 
(B)  Renal arteries supply blood to the kidney with afferent and efferent arterioles 
lead into one of the two different types of capillary beds: peritubular capillaries 
and vasa recta. 
(C) The magnified view of a juxtaglomerular apparatus. 
Diagram adapted from (Principles of Human Physiology, Pearson Education 
Subscription and End-User License Agreement. Access code: USWSP4-FROMM-
STEAK-NEMAN-PLANT-MINES; Expire date: DEC 30, 2013). 
(B) 
(C) 
(A) 
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1.2 Heart 
1.2.1 The gross anatomy 
The word “Cardiac” is derived from the Greek word “Kardia” which mean 
“Heart”. The heart is a muscular organ found in all animals whose main function is to 
generate the force that propel blood for the circulation to the entire body via blood 
vessels by rhythmic contraction (Cohen, 2004). 
 
Essentially, the exact location of the heart is centrally positioned in the thoracic 
cavity above the diaphragm that separates the thoracic cavity from the abdominal cavity. 
In human, the heart is about 300 to 350 grams in males and 250 to 300 grams in females. 
It is covered by a membranous sac called pericardium that possesses a special fluid that 
lubricates the heart when it beats. A healthy heart beats about 60 to 80 times per minute 
(Robb & Robb, 1992). 
 
The human heart can be divided into four chambers. The upper two chambers 
called atria which receive blood that is transported back to the heart from the vasculature 
system and two lower chambers called ventricles. The ventricles receive blood from 
both atria and generate the force to propel the blood away from the heart via the blood 
vessels. The atria and ventricles are separated by a septum that prevents blood mixing 
between the left heart and right heart. The septum that separates the left and right atrium 
is known as interatrial septum whereas the one that separates the left and right ventricle 
is the interventricular septum. Just like the heart has both left and right sides, there is 
another pattern called as “top” and “bottom”. The broader upper pole of the heart is 
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known as the base. In contrast, the lower pole is called as the apex (Dickstein et al., 
2008).  
 
Basically, the heart wall is made up of three layers: an epicardium which is the 
outermost layer of connective tissue, a middle layer called myocardium and an inner 
layer called endothelium which extends throughout the entire cardiovascular system. 
The heart pumps by the continuous rhythmic contraction and relaxation of the 
myocardium because this connective tissue is composed of muscles with contractile 
properties. When the muscle in the atrium and ventricle walls contracts, the mechanical 
forces move the wall inward and squeeze the blood into the chamber. As the squeezing 
increases, the pressure within both atrium and ventricle force the blood out. The atrium 
and ventricle expands and fill with blood when the muscle relaxes (Anderson, 2000). 
The heart contracts by a continuous rhythm called cardiac cycle. This event causes 
pressures in the heart chambers to fluctuate; therefore, it is very crucial that blood flow 
in the heart is only unidirectional. This is made possible by the presence of the four 
types of valves that consists of left and right atrioventricular valves called bicuspid valve 
or sometime referred as mitral valve and a tricuspid valve which allow the blood flow 
only from the atrium to ventricle; the aortic semilunar valve and pulmonary semilunar 
valve also perform the same function to permit blood flow forward at the same time 
preventing it from flowing backward (Marieb & Hoehn, 2007b).    
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1.2.2 The physiology of heart 
The cardiac contractions are governed by an elaborate conduction system that 
determines the series of excitation of cardiac muscle cells. Normally the heartbeat is 
modulated by pacemaker in the sinoatrial node which is situated in the upper right 
atrium where it joins with superior vena cava and the atrioventricular node which is 
situated near the tricuspid valve in the interatrial septum. Succeeding each action 
potential, pacemaker cells exhibit slow spontaneous depolarization. This eventually 
triggers the next action potential which causes the left ventricle to pump oxygenated 
blood into the aorta whose branches transport blood to capillary beds of all tissue and 
organs in the systemic circuit. The deoxygenated blood that returned from the systemic 
tissues then travels back to the heart via the vena cave into the right atrium. From the 
right atrium, blood flows through the tricuspid valve into the right ventricle and later it is 
pumps into the pulmonary artery which carry the deoxygenated blood to the lungs for 
gaseous exchange. At this juncture, blood becomes oxygenated and then travels to the 
left atrium via the pulmonary veins. From the left atrium, blood flows through the 
bicuspid valve into the left ventricle where the whole cycle then repeats (Germann et al., 
2005a).  
 
The cardiac cycle involves the events of one heartbeat by which a complete cycle 
involves the ventricular contraction and relaxation that refers to one systole followed by 
one diastole. However, the duration of this event is not equal. For instance, the heartbeat 
at the normal resting human is 72 beats per minutes. Thus, one beat or one cardiac cycle 
is 0.8 second. Systole lasts about 0.3 second whereas diastole lasts for only 0.5 second 
(Hall & Guyton, 2006b).    
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Figure 1.2: Anatomy and location of the heart. 
(A)  Relative positions of the heart in the thoracic cavity. 
(B)  A cutaway view of the heart with four chambers and valves connecting to major 
blood vessels. 
 
Diagram adapted from (Principles of Human Physiology, Pearson Education 
Subscription and End-User License Agreement. Access code: USWSP4-FROMM-
STEAK-NEMAN-PLANT-MINES; Expire date: DEC 30, 2013). 
 
 
 
 
(A) 
(B) 
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1.3 The blood vessels  
1.3.1 The gross anatomy and physiology 
The human vasculature systems are the part of the circulatory system that 
transports blood throughout the body. The blood vessels consist of three major types of 
blood vessels which are arteries, veins and capillaries. The arteries carry the blood away 
from the heart and reach the capillaries for the actual exchange of water and chemicals 
between the blood and the tissues then the veins carry blood from the capillaries back 
toward the heart (Marieb & Hoehn, 2007a).  
 
Basically, all blood vessels possess a hollow interior called the lumen with its 
surface lined by a layer of epithelium cells called endothelium. Surrounding the lumen is 
a wall that has different composition and thickness from one type of vessels to another. 
The walls of large artery contain large amount of fibrous elastic tissue which enable the 
artery to withstand high blood pressure. In contrary, vein has approximately the same 
diameter like artery but has walls about one-half as thick. The thinness of the vein 
reflects the fact that the blood pressure in the vein is relatively lower than artery. Unlike 
other blood vessels, the vein is equipped with one way valves to prevent the blood back 
flow toward organs and tissues. The smallest blood vessel, capillary has only a layer of 
endothelial cells and basement membrane. The thin wall provide small diffusion 
distance between blood and surrounding interstitial fluid for gaseous exchange like 
oxygen, carbon dioxide as well as electrolytes exchange (Kahle et al., 1993). 
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Figure 1.3: Anatomy and structure of blood vessels.  
Diagram adapted from (Principles of Human Physiology, Pearson Education 
Subscription and End-User License Agreement. Access code: USWSP4-FROMM-
STEAK-NEMAN-PLANT-MINES; Expire date: DEC 30, 2013). 
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1.4 The current issue on kidney disease 
The study on chronic renal disease (CKD) has recently captured the minds of 
many medical professionals. It has become a major health burden to the people of many 
nations either in developed or developing countries. In developing economies, the major 
concern is on the continuous rising incidence of renal disease as it increases the 
expenses in a treatment modality that consumes a disproportionate share of the health 
care budget (Hooi et al., 2005). CKD affects 500 million people worldwide and 
according to the annual report from Ministry of Health Malaysia, out of 26 million 
Malaysian populations, 1 in 10 Malaysian suffers from renal CKD. Annually, 
approximately 2500 people are diagnosed to have renal diseases.  In fact hypertension 
and diabetes are the major culprits of kidney failure that have taken up over 2/3 of 
kidney failure cases (Malaysia, 2011). 
 
The kidney is affected by many chemicals that are derived from dietary intakes; 
some of them may even lead to renal diseases (Pfaller & Gstraunthaler, 1998). 
Undoubtedly, there are several factors that determine the susceptibility of an organ to 
toxicity. These factors include the pharmacokinetics and metabolic fate of the compound. 
Other factor such as the capability of the target organ to response to the toxic insult is 
also important. The kidney is able to metabolize chemicals and reactive intermediates. 
However, in situ metabolic activation of chemicals could lead to selective toxicity to 
cellular macromolecules via generation of reactive oxygen species. This eventually leads 
to peroxidative damage of functionally important cellular structure like nucleic acids and 
plasma membrane (Wirthensohn & Guder, 1986).  
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 Renal failure or kidney failure, formerly called chronic renal insufficiency or 
renal insufficiency is a medical condition that describes a condition in which the kidneys 
fail to meet the body’s function adequately to excrete the filtered toxins and waste 
products from blood such as electrolytes, water, acid-base balance and the end product 
of protein metabolism. Biochemically, it is detected by an elevated serum creatinine 
level. Physiologically, renal failure is described as a derangement in the glomerular 
filtration rate. Generally, renal failure can be divided into three categories: acute, chronic 
and acute on chronic stages. Either form may be due to a large number of other medical 
problems (Levey et al., 2003). Acute renal failure usually occurs as the result of a 
sudden interruption in the blood supply to the kidney or as a result of a toxic overload of 
the kidneys. However, chronic renal failure is more deleterious than acute renal failure. 
The symptoms may not be prominent until the kidneys are extremely damaged over a 
period of months or years.  As opposed to chronic kidney disease, the acute failure 
kidneys can often recover as a result of supportive treatment, but they often remain at an 
increased risk of developing future kidney failure (Bellomo et al., 2004).  
 
 
1.4.1 In-depth view on chronic renal failure 
The progression of chronic renal failure (CRF) is characterized by an irreversible 
deterioration of renal function that gradually progresses to end-stage renal disease (Yu, 
2003). The reason behind the relentless progression of CRF in diverse origins still 
remains unknown but is thought to be multifactorial. Many diseases can irreversibly 
injure or damage the kidneys. Therefore, acute renal failure can proceed into chronic 
stage if the kidney function does not restore after treatment. However, many of them 
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have claimed that the major causes of CRF are closely related to hypertension, obesity 
and diabetes (Odigie & Marin-Grez, 2010; Chen et al., 2004; Vanholder et al., 2005).  
 
Essentially, progressive CRF is characterized via histological alterations of 
tubulointerstitial and glomerular injuries. Indeed, renal dysfunction and outcome in CRF 
condition correlate better with tubulointerstitial injury than glomerular injury. An 
experiment in rat model has revealed that the extent of injury in tubulointerstitial region 
could even exceed that of glomerular region (Kimura et al., 1999). Nevertheless, the 
causes of CRF are heterogeneous. Furthermore, the locations and mechanisms of the 
initial injury may also deviate. Several morphological features are prominent during 
CRF. Fibrosis, loss of normal renal cells via apoptosis and infiltration of leukocytes like 
monocytes and macrophages are the common observation in the diseased kidney. This 
accounts for the end result of the constant interplay between vasoactive substances for 
instance, the growth factors and inflammatory factors activation including cytokines (Yu, 
2003). Moreover, tubular epithelial cells are capable of secreting interstitial collagens, 
proteoglycans and fibronectin, which indicates the degree of transformation of tubular 
epithelial cells into fibroblasts. Apart from histological changes, alteration in the 
extracellular matrix composition has also been demonstrated which in turn affect the 
gene regulation (Kimura et al., 1999). When the renal dysfunction moves from mild to 
moderately severe, diseased kidneys direct the vasoactive hormones production such as 
angiotensin II that increase blood pressure (Vaziri et al., 2007). Meanwhile, the 
participation of renin-angiotensin aldosterone system (RAAS) and activation of renal 
sympathetic activity that leads to the development of chronic hypertension could also 
lead to CRF development (Appel et al., 2008). These significant disruptions of the renal 
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functional processes could trigger a chain of events that culminates in the progression of 
kidney dysfunction; continuous deterioration of this remnant diseased kidney functions 
and structure. Moreover this is associated with and largely mediated by profound 
alteration on renal haemodynamics, inflammation and oxidative stress. This results in 
the up-regulation of ROS in the kidney and cardiovascular tissue, that eventually 
advances to renal injury and compound haemodynamic abnormalities (Vaziri et al., 
2007).      
 
    
Figure 1.4: Schematic representation of the chronic renal failure hypothesis. 
Diagram adapted and redrawn with modification from (Norman & Fine, 2006). 
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1.5 Hypertension 
Essentially, hypertension is a condition by which the blood pressure in the 
arteries is chronically elevated. According to the statistical findings from the Third 
National Health and Morbidity Survey of 2012, in Malaysia it is now estimated 4.8 
million individuals are suffering from hypertension (Sathiabalan, 2012). Moreover, the 
estimated number in worldwide is almost staggering number of 1 billion individuals. It 
is however, alarming because hypertension has become the major risk factor for 
cardiovascular, cerebrovascular and chronic renal diseases (Malaysia, 2009). This 
condition is associated with the elevation of peripheral vascular resistance and structural 
alteration in the wall of blood vessels (Folkow, 1990). 
 
Hypertension is medically defined as the persistent elevated resting blood 
pressure that exceeds 120 mmHg of systolic and 80 mmHg diastolic blood pressures. 
Fundamentally, there are two main types of hypertension, primary and secondary 
hypertension. Primary or essential hypertension consists of 90-95% of all the 
hypertension cases. However till now, the detail cause of primary hypertension remains 
unknown. In secondary hypertension, the elevated blood pressure happen secondary to 
another disease. For instances: renal hypertension is associated with kidney disease 
whereas endocrine hypertension is associated with inappropriate secretion of a hormone 
(Germann et al., 2005c).  
 
In renal hypertension, the principal cause is the disorder of the kidney function. 
In renal failure, the kidney fails to excrete normal amounts of salt and water. This leads 
to water retention and expansion of blood volume. Sometimes, the resistance of blood 
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flow within a kidney or into the kidney can also be the factor that triggers the 
inappropriate release of high renin levels. Abnormally high production of renin leads to 
overproduction of angiotensin II in the plasma which stimulates vasoconstriction. Which 
in turn increases peripheral resistance and also induces the kidney to retain water and 
salt (Ausiello et al., 2003).  Hypertension cause by endocrine disorder happens when 
adrenal medulla over secretes vasoactive hormones such as epinephrine, which increases 
cardiac output and total peripheral resistance. These increases then elevate blood 
pressure (Douglas, 2000). Other factors that contribute to hypertension include 
sympathetic activity, endothelin levels, oxidative stress, declined levels of nitric oxide 
and medullary vasodilation factors (Yu, 2003; Hostetter, 2004; Vaziri & Rodriguez-
Iturbe, 2006). However, the elevation of blood pressure is not limited to the basic cause 
of increased reactive oxygen species (ROS) formation (Vaziri & Rodriguez-Iturbe, 
2006). The increase in oxidative stress has also been reported in various experimental 
models such as Dahl salt-sensitive hypertension, spontaneous hypertensive rat model, 
angiotensin II-induced hypertension and many more. Other than ROS generation, the 
increased activation of uncoupling endothelial nitric oxide synthase (Ausiello et al. 
2003), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine 
oxidase and generation of superoxide also contribute to the development of hypertension 
(Turrin et al., 1994). The endothelium-mediated vasodilatation factor is also reduced 
during hypertension due to low bioavailability of nitric oxide (NOx). The interaction of 
superoxide anion (O2-) and NOx lead to the formation of a weak vasodilator molecule 
called peroxynitrite (OONO-) that has pro-inflammatory properties and impairs the 
vascular structure (Shihab et al., 2003). Chronic administration of superoxide dismutase 
(SOD) mimetic and antioxidant may prevent the development of hypertension in animal 
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models by preventing the occurrence of vascular inflammation and regress vascular 
remodeling via the improvement of endothelial relaxation function (Schnackenberg & 
Wilcox, 1999).  
 
 
Table 1.1: Classification of blood pressure for adults age 18 and older. 
 
Category Systolic (mmHg) Diastolic (mmHg) 
Optimal <120 <80 
       Pre-Hypertension 120-139 80-89 
Stage 1 Hypertension 140-159 90-99 
Stage 2 Hypertension 160-179 100-109 
Stage 3 Hypertension >180 >110 
Adapted from (Norman & Fine, 2006; Malaysia, 2009).  
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1.6 Renin angiotensin aldosterone system  
The renin-angiotensin-aldosterone system or renin-angiotensin system (RAS) is a 
hormonal cascade system that plays a vital role in homeostatic control of blood volume, 
systemic vascular resistance, tissue perfusion, electrolyte and extracellular volume that 
influence arterial pressure and cardiac output. It has become a hot issue of research since 
it turns out to be the backbone in the pathogenesis of many diseases including 
hypertension, cardiovascular and renal diseases (Siragy & Carey, 2010). As the name 
indicates, there are three important elements in this system which consists of renin, 
angiotensin, and aldosterone in order for the system to function (Halter et al., 2009).  
 
The RAS hormonal cascade starts with the biosynthesis of renin by the 
juxtaglomerular cells located mainly in afferent and some efferent arterioles of the renal 
glomerulus. The activity of RAS in the circulation is primarily dependent on the activity 
of the key regulator called enzyme protease renin. Renin is synthesized in the form of 
preprohormone and the active renin is formed via the proteolytic removal of a 43 amino 
acid prosegment peptide from the N-terminus of pro-renin or renin precursor. This active 
renin is then stored in the granules of the juxtaglomerular cells and released through an 
exocytotic process that involves stimulus-secretion coupling into the renal and the 
systemic circulation. However, under normal conditions, there is some small quantity of 
renin remaining in the local fluids of the kidney that can initiate several intrarenal 
functions in response to different disease condition (Remuzzi et al., 2005). 
 
The regulation of renin secretion is a main determinant of the activity of the RAS. 
Principally, active renin secretion is regulated by 4 interdependent factors that include: 
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(1) renal baroreceptor in the afferent arterioles called “polkissen” cells that detect 
changes in renal perfusion pressure, (2) the “macula densa” cells in the juxtaglomerular 
apparatus that sense changes in NaCl concentration, (3) stimulation of sympathetic 
nerves activity by adrenergic receptor and (4) the direct negative feedback action of Ang 
II on the juxtaglomerular cells (Laragh & Sealey, 1992). The production of renin is 
regulated by the initial limiting step of the RAS, where the N-terminal portion of a large 
molecular weight globulin called renin substrate or angiotensinogen which is produced 
from liver to form the biologically inert decapeptide Angiotensin I (Ang I). The inactive 
decapeptide Ang I is further hydrolyzed by angiotensin converting enzyme (ACE) 
through the removal of the C-terminal dipeptide to form the biologically active potent 
vasoconstrictor octapeptide Ang II.  Ang II is metabolized to Angiotensin III (Ang III) 
and then to Angiotensin IV (Ang IV) by angiotensinases that are located in the vascular 
beds and red blood cells of most tissues that have presser activity on Ang II (Kobori et 
al., 2007).  
 
Figure 1.5: Schematic representation of the renin angiotensin aldosterone system. 
Diagram adapted from http://en.wikipedia.org/wiki/File:Renin-angiotensin-
aldosterone_system.png. 
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1.6.1 Role of angiotensin II 
Although there are many angiotensin subtypes like Ang III and Ang IV in the 
circulation, Ang II is the primary powerful active effector in RAS that can induce 
several physiological and pathophysiological actions. Physiologically, Ang II enhances 
myocardiac contractility, increases the sympathetic nerve activity, modulates smooth 
muscle constriction, stimulates catecholamines, aldosterone production from adrenal 
medulla and stimulates salt craving and thirst. However, during pathophysiological 
conditions, Ang II induces inflammation, apoptosis, and cell proliferation that leads to 
the dysregulation of gene expression in biologically active substances via multiple 
intracellular signaling pathways that lead to tissue injury (Timmermans et al., 1993). It 
has been proven in animal studies that increased circulatory Ang II levels could enhance 
the risk for cardiovascular and renal disorders (Navar, 1997). Moreover, 
pharmacological investigation with angiotensin converting enzyme (ACE) inhibitor and 
angiotensin receptor blocker (ARB) has shown that Ang II exerts a cardinal role in 
pathogenesis of renal injury and hypertension in both preclinical and clinical stages. This 
is primarily due to the fact that the kidney plays a vital role for hypertension 
development, as hypertension is both a victim and culprit of renal diseases (Paul et al., 
2006).  
 
 
1.6.2 Angiotensin II receptors 
As already mentioned, the major biological actions of Ang II in the kidney are 
mediated by well characterized receptors. At least 4 types of angiotensin receptor 
subtypes have been described (Stanton, 2003). Angiotensin II type 1 (AT1) receptor is a 
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typical G protein-coupled receptor (GPCR) superfamily that contains 7 trans-membrane 
spanning sequences, which are widely distributed on many cell types in Ang II target 
organs. Normally, the AT1 receptor mediating most of the established physiological and 
pathophysiological effects of Ang II that includes the vasoconstriction and increase of 
blood pressure in the cardiovascular system. In the kidney, it enhances renal tubular 
sodium reabsorption and inhibits the release of renin. Other than this, AT1 receptor also 
mediates the effects of Ang II on cell growth and proliferation, inflammatory response, 
oxidative stress, increase sympathetic activity and stimulate the production of 
aldosterone in adrenal cortex (Higashi et al., 2002; Carey et al., 2000). In rodents, there 
are two types of AT1 receptor subtypes. AT1a  receptor is predominant in all nephron 
segments whereas AT1b is more abundant in the glomerular region (Bouby et al., 1997).  
 
The Angiotensin II type 2 (AT2) receptor is however abundant in fetal life as 
compared to adult. The main function of AT2 receptor is to mediate the vasodilation and 
anti-proliferative and apoptotic effects in vascular smooth muscle and prevent the 
growth and remodeling in the heart (Brewster et al., 2003). However in kidney, AT2 
receptor may influence proximal tubule sodium reabsorption and stimulate the 
conversion of renal prostaglandin E2 to prostaglandin F2α but the importance of these 
AT2 mediated action still unknown (Atlas, 2007). When both AT1 and AT2 subtypes are 
co-expressed in the same cell, the action of AT1 receptor mediated response could be 
antagonized by AT2 receptor due to the nature of hetero-dimerization properties between 
the two receptors (Carey et al., 2000). The type 4 (AT4) receptor is thought to mediate 
the action of plasminogen activator inhibitor 1 by Ang II via the N-terminal truncated 
peptides of Ang III and Ang IV but the exact function of the type 3 (AT3) receptor 
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remains unknown (Stanton, 2003). However, others have reported that its function is to 
stimulate aldosterone secretion and is involved in thirst (Rang et al., 2007a).  
 
 
 
Figure 1.6: Schematic diagram of the renin angiotensin aldosterone system and its 
subtypes.  
Diagram adapted and redrawn with modification from (Brewster & Perazella, 2004; 
Atlas, 2007). 
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1.7 Sympathetic nervous system 
The nervous system as a whole consists of the central nervous system (CNS), 
notably the brain and spinal cord, and the peripheral nervous system (PNS), where the 
nerve fibers connecting all parts of the body with the central nervous system. The PNS is 
divided into a sensory (afferent) and motor (efferent) with the afferent division that 
conveys impulses to the CNS and efferent division carrying impulses away from the 
CNS out to the peripheral organs for an effect or action. The efferent division in PNS is 
further subdivided into two branches, the somatic nervous system and the autonomic 
nervous system (ANS). All these nerves are outside the CNS. The somatic nervous 
system controls musculoskeletal movement, and conducts sensory messages from the 
body to the CNS. On the other hand, the ANS has two branches namely sympathetic and 
parasympathetic divisions, which regulate the involuntary processes of the body, the 
viscera, blood vessels, sense organs and glands. It is called autonomic because it is 
believed to function autonomously. Autonomic also indicates self-regulating and this is 
a key principle of all body systems which depend on constant feedback for homeostasis. 
In standard physiology the two parts of the ANS have been perceived as functioning 
reciprocally: the sympathetic governing the fight or flight reaction and the 
parasympathetic involving restorative, relaxation and recuperation function (Germann et 
al., 2005d).  
 
The sympathetic nervous system is activated by any stimulus over an 
individual’s threshold which can vary enormously, including feelings, and by noise, 
light, drugs and chemicals (e.g. caffeine). In response to the stimulus an immediate 
anticipatory state is generated by the release of neurotransmitters such as acetylcholine 
